Skip to main content

Table 2 Correlation of BRAF Mutation with clinico-pathological parameters in colorectal carcinoma

From: A very low incidence of BRAF mutations in Middle Eastern colorectal carcinoma

  Total Positive Negative P value
  N % N % N %
Total number of cases 757   19 2.5 738 97.5  
Age        
  < 50 years 246 32.5 3 1.2 243 98.8 0.0938
  > 50 years 511 67.5 16 3.1 495 97.9  
Sex        
  Male 394 52.0 11 2.8 383 97.2 0.6044
  Female 363 48.0 8 2.2 355 97.8  
Tumour site*        
  Left colon 600 83.0 10 1.7 590 98.3 0.0019
  Right colon 123 17.0 9 7.3 114 92.7  
Histological type        
  Adenocarcinoma 673 88.9 18 2.7 655 97.3 0.3673
  Mucinous Carcinoma 84 11.1 1 1.2 83 98.8  
Tumour stage*        
  I 88 12.2 4 4.6 84 95.4 0.6853
  II 255 35.3 7 2.7 248 97.3  
  III 289 40.0 6 2.1 283 97.9  
  IV 90 12.5 2 2.2 88 97.8  
Differentiation        
  Well 74 9.8 2 2.7 72 97.3 0.8887
  Moderate 590 77.9 14 2.4 576 97.6  
  Poor 93 12.3 3 3.2 90 96.8  
MSI-Molecular*        
  MSI-H 81 11.1 6 7.4 75 92.6 0.0144
  MSI-S/L 651 88.9 13 2.0 638 98.0  
KRAS Mutation*        
  Positive 216 28.7 2 0.9 214 99.1 0.0518
  Negative 537 71.3 17 3.2 520 96.8  
CIMP*        
  High 24 5.1 4 16.7 20 83.3 0.0017
  Low & middle 444 94.9 8 1.8 436 98.2  
  1. *Data were not available (NA) for some cases for tumor site (NA = 34), Stage (NA = 35), MSI-Molecular (NA = 25), KRAS Mutation (NA = 4), and CIMP (NA = 289).